The figure below details our products edge in comparison to our competition. The donor cornea is the status quo for treatment especially for countries like the United States which have a surplus of donor tissues, but in low-income countries such as India, where insurance is not common, affordability (donor tissue transplants are upwards of $16,000) and availability of donor tissues may prove to be a problem. Donor tissues also run the risk of tissue rejection and infection.
Our main competitor for the artificial corneas market is the Boston K-pro. The Boston K-pro still requires a donor tissue and still bears the chance of rejection. On top of this, Boston K-pro patients require follow-up surgeries because of their short service life. Our edge to these existing solutions is the fact that our solution is affordable and bactericidal which lowers the chance of infection and does not have additional costs after the surgery such as antibacterial eye drops. NanoCurv guarantees a longer service life compared to its competition.
